Johnson & Johnson‘s (NYSE:JNJ) Janssen and Apple (NSDQ:AAPL) said today that the two companies inked a deal to study if an app from J&J in combination with the Apple Watch’s ECG app and irregular rhythm notifications can improve outcomes for people living with atrial fibrillation.
The study is slated to measure the impact of the Apple Watch on the early detection and diagnosis of AFib, as well as the efficacy of a medication adherence program.
The two companies plan to launch a multi-year research program later this year.
“We’re excited about the potential of common, wearable technology to aid in the earlier detection and prevention of a frequent cause of stroke,” Dr. Paul Stoffels, J&J’s vice chair of the executive committee & CSO, said in prepared remarks. “Too many people living with AFib are unaware of their risk, and earlier detection, diagnosis and treatment of AFib could significantly improve outcomes. Based on the insights generated through this research program, we may be able to develop new ways to detect other health conditions earlier in the future that also exhibit measurable physiological symptoms.”
“Through Apple Watch people have been able to learn more about their heart health, including discovering they have AFib. This kind of information empowers customers to follow up with the right treatment or even better, implement healthy habits aimed at prevention,” Apple’s COO, Jeff Williams added.
“This collaboration brings together Johnson & Johnson’s depth of expertise and long heritage in treating cardiovascular disease with Apple’s experience in utilizing cutting-edge technologies to improve the lives of consumers. Ultimately, we hope to improve the treatment of cardiovascular disease, and identify ways to prevent it,” Dr. Paul Burton, VP of medical affairs for Janssen’s internal medicine unit, said.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.